SMO and basal cell carcinoma: SMO inhibitors have shown high efficacy in patients with basal cell carcinoma (BCC) harboring activating mutations in the Hh pathway, leading to the approval of vismodegib and sonidegib, two SMO inhibitors, as therapies for advanced BCC 60.